Unlearn.AI is a biotech AI company that develops a digital twin service for clinical trials. Digital twins enhance healthcare by assessing health risks before a disease manifests its symptoms, according to some experts. Unlearn brings together a world-class team of experts across pharma, medtech, machine learning, and business who share a vision of using machine learning and biostatistics to improve clinical trials for the benefit of patients and sponsors.
Unlearn invented their TwinRCT solution to enable biopharma partners to run faster, more successful clinical trials. A TwinRCT is a randomized trial that uses machine learning to achieve a higher probability of success with a smaller number of patients. As in a traditional RCT, patients are randomized to a treatment group and a control group, but, unlike a traditional trial, a prognostic digital twin is created for every patient using a machine learning model trained on historical data. The treatment effects for the primary and secondary outcomes can all be estimated from the trial with greater precision after correcting for a prognostic score derived for each patient's digital twin.
TwinRCTs provide a scientifically sound method for using deep learning and historical patient data to improve clinical trials.
Total raised
$135M
Last stage
Series C
Investors
Charles K. Fisher
Scientist at the intersection of physics, machine learning, and computational biology. Holds a Ph.D. in biophysics from Harvard University. Previously a machine learning engineer at Leap Motion and computational biologist at Pfizer.
LinkedInJonathan Walsh
Co-founded Unlearn.AI. Background in data science and machine learning with a PhD in theoretical physics.
No applications, no recruiter spam. Just the intro.
A few questions to make sure this role is the right shape for you. Two minutes.
I write the intro, send it to the founder, and handle the back-and-forth.
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.